title: Inflammatory breast cancer: an overview.
abstract: Inflammatory breast cancer (IBC) is the most aggressive entity of breast cancer. Management involves coordination of multidisciplinary management and usually includes neoadjuvant chemotherapy, ablative surgery if a tumor-free resection margin is expected and locoregional radiotherapy. This multimodal therapeutic approach has significantly improved patient survival. However, the median overall survival among women with IBC is still poor. By elucidating the biologic characteristics of IBC, new treatment options may become available. We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. The objective of the current review is to present an overview of the literature related to the biology, imaging and multidisciplinary treatment of inflammatory breast cancer.
authors.affiliation: Department of Surgery, Canisius Wilhelmina Hospital, Postbus 9015, 6500 GS Nijmegen, The Netherlands. Electronic address: djpvanuden@gmail.com.
authors.forename: D J P
authors.initials: DJ
authors.lastname: van Uden
authors.affiliation: Medical Oncology, Academic Medical Center, University of Amsterdam, Postbus 22660, 1100 DD Amsterdam, The Netherlands.
authors.forename: H W M
authors.initials: HW
authors.lastname: van Laarhoven
authors.affiliation: Institute for Radiation Oncology, Postbus 60160, 6800 JD Arnhem, The Netherlands.
authors.forename: A H
authors.initials: AH
authors.lastname: Westenberg
authors.affiliation: Department of Surgery, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands.
authors.forename: J H W
authors.initials: JH
authors.lastname: de Wilt
authors.affiliation: Department of Surgery, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands.
authors.forename: C F J M
authors.initials: CF
authors.lastname: Blanken-Peeters
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005260:Female; D005720:Gamma Rays / Q000627:therapeutic use*; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008207:Lymphatic Metastasis; D008408:Mastectomy / Q000379:methods; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D011956:Receptors, Cell Surface / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D043925:Angiogenesis Inducing Agents; D000970:Antineoplastic Agents; D011956:Receptors, Cell Surface; D066246:ErbB Receptors
keywords: Inflammatory breast cancer; Molecular characteristics; Surgery; Treatment